PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Sanofi’s Sarclisa rejected by NICE over uncertainties on total benefit, cost-effectiveness

Sanofi is making a push back into oncology led by multiple myeloma drug Sarclisa, its first wholly-owned cancer medicine in a decade. But now the company’s forthcoming U.K. rollout has hit a snag thanks to cost watchdogs.

In new draft guidance, the National Institute for Health and Care Excellence (NICE) said that just how much benefit Sarclisa provides to patients versus the standard care is unknown, and that cost-effectiveness estimates for the drug are outside of recommended ranges. 

Sanofi’s Sarclisa scored a recommendation from Europe’s Committee for Medicinal Products for Human Use back in March in combo with Bristol Myers Squibb’s Pomalyst and dexamethasone (pom-dex) for patients with relapsed and refractory multiple myeloma who have received at least two prior therapies. The European Commission approved the drug last week.

For its part, Sanofi is positioning the med as a fourth-line treatment, NICE says, to be used after three prior therapies. As it stands, current fourth-line treatment includes pom-dex alone or Johnson & Johnson’s Darzalex, provided through the Cancer Drugs Fund. 

Sarclisa delays disease progression and extends patients’ lives compared with pom-dex alone, NICE says, but a trial comparing the treatments isn’t finished yet?—and that means Sarclisa’s overall benefit is unknown. Plus, cost-effectiveness estimates “are much higher than what NICE normally considers a cost-effective use of NHS resources,” the draft guidance said.

The drug’s list price isn’t yet public. NICE’s decision isn’t final and is subject to review and consultation. 

Meanwhile, Sanofi’s Sarclisa won an FDA approval in March, and it’s already chasing another. The drug recently posted positive data in combo with Amgen’s Kyprolis, setting it up to potentially challenge Darzalex.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026